Aurobindo Pharma is currently trading at Rs. 117.10, up by 2.45 points or 2.14% from its previous closing of Rs. 114.65 on the BSE.
The scrip opened at Rs. 116.00 and has touched a high and low of Rs. 118.50 and Rs. 115.80 respectively. So far 33,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 206.00 on 07-Apr-2011 and a 52 week low of Rs. 80.35 on 18-Nov-2011.
Last one week high and low of the scrip stood at Rs. 120.75 and Rs. 111.80 respectively. The current market cap of the company is Rs. 3,408.00 crore.
The promoters holding in the company stood at 54.73% while Institutions and Non-Institutions held 30.00% and 15.27% respectively.
Aurobindo Pharma has received final approvals from the US Food & Drug Administration (USFDA) to market Quetiapine Fumarate Tablets 25mg, 50mg, l00 mg, I50 mg, 200mg, 300mg and 400mg.
Quetiapine Fumarate Tablets are the generic equivalent of AstraZeneca LP's Seroquel Tablets 25mg, 50mg, l00mg, 150mg, 200mg, 300mg and 400mg. Quetiapine Fumarate Tablets are indicated for the treatment of serious psychotic disorders such as Schizophrenia and Bipolar Disorder and falls under the Neurological (CNS) therapeutic category.
The product has been approved out of Unit 111 facility in Hyderabad, India. The company has a total of 147 ANDA approvals (118 final approvals and 29 tentative approvals) from USFDA.
Aurobindo Pharma has a product presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardio-vascular, gastroenterology, etc. The company is the market leader in semi-synthetic penicillin drugs.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1777.65 |
Dr. Reddys Lab | 1194.55 |
Cipla | 1465.65 |
Lupin | 2043.30 |
Zydus Lifesciences | 944.25 |
View more.. |